Understand Japan's PMDA regulatory requirements for device modifications
Manufacturers marketing medical devices in Japan are generally required to notify the Pharmaceuticals and Medical Devices Agency (PMDA) or the relevant Registered Certification Body (RCB) of post-market modifications to authorized devices. These may include changes to design specifications, manufacturing processes, materials, manufacturing sites, software, labeling and intended use.
The appropriate regulatory procedure depends on the modification and the device’s original registration route. Failure to follow applicable requirements may result in regulatory noncompliance, market disruption or product recalls.
Determine the appropriate pathway for a device change
This white paper explains how post-market device modifications are managed under Japan's Pharmaceuticals and Medical Devices Act (PMD Act). Depending on the modification, one of four regulatory pathways may apply:
- No Action Required
- Change Notification
- Change Application
- New Submission
Fundamental modifications, such as certain changes to intended use, operating principles or other core device characteristics, may require a New Submission.
How Japan medical device regulations address post-market changes
The role of MHLW
Japan's Ministry of Health, Labour and Welfare (MHLW) has not published a single, comprehensive decision tree covering all post-market device modifications. Manufacturers must evaluate proposed changes using the PMDA decision tree and applicable MHLW notices and regulatory guidance.
The appropriate procedure may also depend on whether the device was registered through Pre-Market Approval (PMA), Pre-Market Certification (PMC) or Pre-Market Notification (PMN).
Regulatory guidance covered through January 2026
This white paper updates and expands on the original PMDA decision tree by incorporating relevant MHLW notices and regulatory guidance issued through January 2026. The English-language framework helps global manufacturers determine the appropriate regulatory pathway for a proposed change.
The revised framework also covers raw materials, manufacturing sites, software as a medical device (SaMD), cybersecurity-related changes and other modification scenarios not fully addressed by the original decision tree.
Evaluate labeling and intended-use changes
Device names, warnings and instructions for use
Manufacturers must assess modifications involving:
- Device names
- Intended use
- Warnings and precautions
- Instructions for use
- Other labeling updates
Certain changes to warnings, contraindications, prohibitions or precautions in the instructions for use may require prior consultation with the PMDA Safety Division.
Changes affecting safety, effectiveness or intended use
Clarification that do not affect safety or effectiveness may qualify for No Action Required or a Change Notification. Changes affecting intended use, invasiveness, method of operation, service life, safety or effectiveness generally require a Change Application.
Assess device design, performance and material changes
Operating principles, device performance and user interfaces
Manufacturers must evaluate modifications to operating principles, energy properties, performance or safety specifications, user interfaces, dimensions, structure and shape.
Changes intended to improve durability or safety, reduce performance or remove a function may qualify as reportable modifications.
Shelf life, sterilization methods, shape and structure
Changes to shelf life, operating life, sterilization methods, dimensions, shape or structure must be evaluated under the applicable MHLW notices and decision-tree criteria. The appropriate pathway depends on whether the modification affects performance, safety, effectiveness, intended use or introduces new risks.
Risk-based assessment of raw material changes
MHLW guidance issued in January 2026 revised the procedures for evaluating raw material changes, placing greater emphasis on rigorous, risk-based decision-making. Manufacturers should consider whether a material change affects device functionality, involves materials that contact the body or introduces new or increased risks. Depending on the assessment, the modification may require a Change Notification, Change Application or New Submission.
Address manufacturing-site changes
Changes involving development, assembly, sterilization or warehouse facilities may require a Change Notification or Change Application. The applicable pathway can depend on the site type, changes to its organization, resources or QMS, and whether the changed or added site holds a valid QMS certificate issued by the PMDA or an RCB.
The white paper also discusses fast-track review for qualifying manufacturing-site Change Applications.
Evaluate changes to software as a medical device
Software as a medical device (SaMD) manufacturers must evaluate modifications using the applicable PMDA decision framework. MHLW guidance provides examples of SaMD-specific modifications that may qualify for a Change Notification or No Action Required when they do not affect software performance or functionality.
Software changes that may require notification
Changes involving online distribution, operating-system types, cloud-based operation, data-recording media or related warehousing arrangements may qualify for a Change Notification.
Software changes that may require no action
Operating-system or database version updates, changes to recommended hardware or distribution media, and licensing adjustments may qualify for No Action Required.
Manufacturers should evaluate each modification against the applicable guidance rather than assume that an example automatically applies to a particular product.
Understand submission timing and IDATEN
Manufacturers must follow the applicable timing and approval requirements for each regulatory pathway:
- A standard Change Notification must be submitted within 30 days after an eligible modification.
- When a Change Application is required, approval must be obtained the modified device is released in Japan.
Under Japan’s Improvement Design within Approval for Timely Evaluation and Notice (IDATEN) system, an accepted post-market design change plan may allow modifications that would otherwise require a Change Application to be handled through an IDATEN Change Notification. IDATEN notifications undergo PMDA review within 30 days.
Download the white paper on medical device change applications in Japan
Download the white paper for guidance on evaluating modifications, selecting the appropriate regulatory pathway and understanding recent regulatory updates.
Manufacturers should work closely with their Marketing Authorization Holder (MAH), Designated Marketing Authorization Holder (DMAH), the PMDA and the relevant RCB when evaluating complex or borderline changes.
Emergo by UL's local regulatory experts can support manufacturers in navigating medical device regulatory requirements and registration in Japan, including requirements related to in vitro diagnostic device labeling.
Frequently asked questions
- Does Japan require additional testing after a medical device change?
Whether additional testing is required depends on the nature and risk of the modification. Changes that affect device performance, safety, shelf life, usability, raw materials or intended use may require supporting evidence such as risk assessments, verification testing, validation testing, clinical evaluation, stability data or other documentation to determine the appropriate regulatory pathway.
Manufacturers should assess whether the change introduces new risks, increases existing risks or affects the device’s safety, effectiveness, performance or intended use.
- Can a change to an IVD follow the same pathway as a change to another medical device?
Potentially. In vitro diagnostic (IVD) devices are regulated under Japan's Pharmaceuticals and Medical Devices Act (PMD Act). Post-market changes generally follow the same framework and may result in No Action Required, a Change Notification, a Change Application or a New Submission.
The appropriate regulatory pathway depends on the device’s classification, original registration route and the nature and significance of the change. Each modification should be evaluated individually under the applicable requirements.
- Does changing a Japanese medical device label affect the original registration?
It can. Labeling changes that affect intended use, warnings, contraindications, prohibitions, precautions, directions for use, safety or effectiveness may require a Change Notification or Change Application.
Minor clarifications that do not affect safety or effectiveness may not require regulatory action, but the manufacturer should still assess and document the change. Revisions to warnings, contraindications, prohibitions or precautions in the instructions for use may also require prior consultation with the PMDA Safety Division.
- When should a manufacturer consult PMDA about a borderline device change?
Manufacturers should consult the PMDA, the relevant RCB, or their local MAH or DMAH when the appropriate regulatory pathway is unclear.
Consultation is especially recommended for borderline cases, modifications related to recalls, field safety corrective actions, adverse events, device failures or situations not clearly addressed by existing guidance or decision trees.
- What information should manufacturers document when determining that no regulatory action is required?
Even when a modification results in No Action Required, the manufacturer must appropriately evaluate, manage and document the change within its quality management system (QMS). Documentation should support the assessment and rationale for concluding that the modification does not require a Change Notification, Change Application or New Submission. This may include the applicable risk analysis and evidence supporting the conclusion that the device’s safety and effectiveness are unaffected.
- Can several related device modifications be assessed together in Japan?
Yes. When multiple changes are planned simultaneously, or when one change affects multiple aspects of a device, manufacturers should evaluate all applicable modification pathways and decision-tree branches. If the analyses indicate different regulatory outcomes, the most stringent pathway applies in the following order:
- New Submission
- Change Application
- Change Notification
- No Action Required
- How can a Change Application affect an existing medical device approval in Japan?
A Change Application must be submitted and approved before the modified device can be marketed in Japan. Depending on the significance of the modification, the approved application may amend the existing approval or introduce additional regulatory requirements. Major changes affecting the intended use, operating principle or other fundamental characteristics may require a New Submission rather than a modification to the existing approval. Marketing the modified device before obtaining the required approval may result in regulatory noncompliance and product recalls.
Request more information from our specialists
Thanks for your interest in our products and services. Let's collect some information so we can connect you with the right person.